Alnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025

Reuters

2025/08/11

Alnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025

Alnylam Pharmaceuticals Inc. has announced the presentation of new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the European Society of Cardiology Congress 2025, scheduled to take place in Madrid, Spain, from August 29 to September 1, 2025. The company will present findings from Cohort A of the KARDIA-3 Phase 2 study, which evaluates the investigational RNAi therapeutic, zilebesiran, for patients with uncontrolled hypertension and high cardiovascular risk. These results will be part of a late-breaking abstract in the Hot Line 4 session on August 30, 2025. Additionally, Alnylam will share data from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), focusing on its impact on transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including 12-month follow-up results and effects on days lost to death and/or hospitalization. The presentations aim to highlight the potential of RNAi therapeutics in transforming cardiovascular disease treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250811966575) on August 11, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2558106650"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558106650\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558106650?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-11 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558106650","market":"fut","top_or_hot":-1,"title":"Alnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alnylam Pharmaceuticals Inc. has announced the presentation of new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the European Society of Cardiology Congress 2025, scheduled to take place in Madrid, Spain, from August 29 to September 1, 2025. The company will present findings from Cohort A of the KARDIA-3 Phase 2 study, which evaluates the investigational RNAi therapeutic, zilebesiran, for patients with uncontrolled hypertension and high cardiovascular risk. These results will be part of a late-breaking abstract in the Hot Line 4 session on August 30, 2025. Additionally, Alnylam will share data from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), focusing on its impact on transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including 12-month follow-up results and effects on days lost to death and/or hospitalization. The presentations aim to highlight the potential of RNAi therapeutics in transforming cardiovascular disease treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250811966575) on August 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-11 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alnylam Pharmaceuticals Inc. has announced the presentation of new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the European Society of Cardiology Congress 2025, scheduled to take place in Madrid, Spain, from August 29 to September 1, 2025. The company will present findings from Cohort A of the KARDIA-3 Phase 2 study, which evaluates the investigational RNAi therapeutic, zilebesiran, for patients with uncontrolled hypertension and high cardiovascular risk. These results will be part of a late-breaking abstract in the Hot Line 4 session on August 30, 2025. Additionally, Alnylam will share data from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), focusing on its impact on transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including 12-month follow-up results and effects on days lost to death and/or hospitalization. The presentations aim to highlight the potential of RNAi therapeutics in transforming cardiovascular disease treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250811966575) on August 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nNDL10cbBx:1","article_id":"2558106650","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558106650","pubTimestamp":1754913776,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alnylam Pharmaceuticals Inc. has announced the presentation of new data from its hypertension and transthyretin amyloidosis  programs at the European Society of Cardiology Congress 2025, scheduled to take place in Madrid, Spain, from August 29 to September 1, 2025. The company will present findings from Cohort A of the KARDIA-3 Phase 2 study, which evaluates the investigational RNAi therapeutic, zilebesiran, for patients with uncontrolled hypertension and high cardiovascular risk. These results will be part of a late-breaking abstract in the Hot Line 4 session on August 30, 2025. Additionally, Alnylam will share data from the HELIOS-B Phase 3 study of AMVUTTRA , focusing on its impact on transthyretin amyloidosis with cardiomyopathy , including 12-month follow-up results and effects on days lost to death and/or hospitalization. The presentations aim to highlight the potential of RNAi therapeutics in transforming cardiovascular disease treatment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4548":"巴美列捷福持仓","BK4139":"生物科技","ALNY":"阿尔尼拉姆制药公司","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"Alnylam Pharmaceuticals在2025年ESC大会上公布了高血压和ATTR项目试验的有希望的新数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":0.9},"content_text":"Alnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025\n    \n\n        Alnylam Pharmaceuticals Inc. has announced the presentation of new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the European Society of Cardiology Congress 2025, scheduled to take place in Madrid, Spain, from August 29 to September 1, 2025. The company will present findings from Cohort A of the KARDIA-3 Phase 2 study, which evaluates the investigational RNAi therapeutic, zilebesiran, for patients with uncontrolled hypertension and high cardiovascular risk. These results will be part of a late-breaking abstract in the Hot Line 4 session on August 30, 2025. Additionally, Alnylam will share data from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), focusing on its impact on transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including 12-month follow-up results and effects on days lost to death and/or hospitalization. The presentations aim to highlight the potential of RNAi therapeutics in transforming cardiovascular disease treatment.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250811966575) on August 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}